Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Castle Biosciences, Inc. (CSTL : NSDQ)

• Company Description    Castle Biosciences Inc. is a commercial-stage dermatological cancer company. It is focused on providing physicians and patients, clinically actionable genomic information. Castle Biosciences Inc. is based in Texas, United States. Number of Employees: 883

• Price / Volume Information    Yesterday's Closing Price: $32.76 Daily Weekly Monthly 20 Day Moving Average: 334,074 shares Shares Outstanding: 30.55 (millions) Market Capitalization: $1,000.80 (millions) Beta: 0.99 52 Week High: $44.28 52 Week Low: $17.72 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 1.61% 2.34% 12 Week 60.12% 56.73% Year To Date -15.78% -24.87%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1500 W. Parkwood Ave Suite 400 - Friendswood,TX 77546 USA ph: 866-788-9007 fax: - ir@castlebiosciences.com https://castlebiosciences.com

• General Corporate Information    Officers Derek J. Maetzold - President and Chief Executive Officer Daniel M. Bradbury - Chairperson of the Board of Directors Frank Stokes - Chief Financial Officer Daniel M. Bradbury - Director Kimberlee S. Caple - Director Peer Information Castle Biosciences, Inc. (CORR.) Castle Biosciences, Inc. (RSPI) Castle Biosciences, Inc. (CGXP) Castle Biosciences, Inc. (BGEN) Castle Biosciences, Inc. (GTBP) Castle Biosciences, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 14843C105 SIC: 8071 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/02/26 Share - Related Items Shares Outstanding: 30.55 Most Recent Split Date: (:1) Beta: 0.99 Market Capitalization: $1,000.80 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.38 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.29 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/02/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.13 Price/Cash Flow: 29.43 Price / Sales: 2.80 EPS Growth vs. Year Ago Period: -146.67% vs. Previous Quarter: 85.71% Sales Growth vs. Year Ago Period: 20.14% vs. Previous Quarter: 23.74% ROE 06/30/26 - -4.15 03/31/26 - -2.77 12/31/25 - -0.89 ROA 06/30/26 - -3.45 03/31/26 - -2.30 12/31/25 - -0.74 Current Ratio 06/30/26 - 6.04 03/31/26 - 6.75 12/31/25 - 5.26 Quick Ratio 06/30/26 - 5.85 03/31/26 - 6.53 12/31/25 - 5.11 Operating Margin 06/30/26 - -5.43 03/31/26 - -3.78 12/31/25 - -1.18 Net Margin 06/30/26 - -5.43 03/31/26 - -3.78 12/31/25 - -7.02 Pre-Tax Margin 06/30/26 - -5.37 03/31/26 - -5.19 12/31/25 - -8.57 Book Value 06/30/26 - 15.39 03/31/26 - 15.21 12/31/25 - 16.13 Inventory Turnover 06/30/26 - 8.14 03/31/26 - 7.97 12/31/25 - 8.33 Debt-to-Equity 06/30/26 - 0.02 03/31/26 - 0.02 12/31/25 - 0.02 Debt-to-Capital 06/30/26 - 1.55 03/31/26 - 1.85 12/31/25 - 2.07

Powered by Zacks Investment Research ©